Loading stock data…
BBIO
$68.61+2.66 (+4.03%)
Market ClosedLast close May 13
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BridgeBio Pharma, Inc. in the Healthcare sector is trading at $68.61. Wall Street consensus targets $103.27 (22 analysts), implying a +50.5% move over the next 12 months. The stock is currently 19% below its 52-week high of $84.94, remaining 5.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +50.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$68.61
Potential Downside
0%
Whystock Fair Value$68.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus22 analysts
Mean target$103.27+50.5%
Range$80.00 – $157.00
Fundamentals
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
37.21%
Volume
Today's trading volume
3.14M
Recent News
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 8, Evercore ISI raised its price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $130 from $125. It maintained an “Outperform” rating on the stock. On May 7, BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted first-quarter 2026 results, showing $194.5 […]
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential near-term product launches from the company’s late-stage pipeline. Tom Trimarchi, BridgeBi
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial
An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.
Analysts Are Updating Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Estimates After Its First-Quarter Results
BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) shareholders are probably feeling a little disappointed, since its shares fell...
BridgeBio Brazil Approval Expands BEYONTTRA Reach While Valuation Signals Upside
BridgeBio Pharma's acoramidis, marketed as BEYONTTRA, has received regulatory approval in Brazil for transthyretin amyloidosis cardiomyopathy. The approval broadens access to BEYONTTRA beyond the US, EU, Japan, and UK into one of Latin America's largest pharmaceutical markets. Commercialization in Brazil is expected to begin later in 2026, following this regulatory milestone. For investors watching BridgeBio Pharma (NasdaqGS:BBIO), the Brazilian approval lands against a backdrop of mixed...